Featured Research

from universities, journals, and other organizations

Regulating The Regulators: New Therapeutic Approach Against Cancer

Date:
September 21, 2009
Source:
Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology
Summary:
The development of cancer involves the uncontrolled growth of normal cells of the body. Our immune system can sense the growth of the tumor cells and can usually eliminate them using direct killing mechanisms, mediated by natural killer cells and cytotoxic T lymphocytes. However, the tumor has an arsenal of strategies to counteract the immune response that seeks to eliminate it. Researchers have developed a new strategy to selectively block the tumor induced immunosuppression and thereby enhance the efficacy of tumor immunotherapeutics.

The development of cancer involves the uncontrolled growth of normal cells of the body. Our immune system can sense the growth of the tumor cells and can usually eliminate them using direct killing mechanisms, mediated by natural killer cells and cytotoxic T lymphocytes. However, the tumor has an arsenal of strategies to counteract the immune response that seeks to eliminate it. Professor Kingston Mills, Trinity College Dublin, has developed a new strategy to selectively block the tumor induced immunosuppression and thereby enhance the efficacy of tumor immunotherapeutics.

Related Articles


First results will be presented during 2nd European Congress of Immunology 2009 in Berlin.

Tumors secrete immunosuppressive molecules that dampen the immune responses and recruit suppressor cells, called regulatory T cells (Treg cells). However, these Treg cells have a protective function in preventing immune responses against self antigens and normal host cells, which, if uncontrolled, can lead to autoimmune diseases. These immunosuppressive molecules and Treg cells make it very difficult for the immune system to kill the growing tumor, and this can lead to uncontrolled tumor growth and cancer.

Cancer is usually treated by surgery, chemotherapy, radiotherapy or a combination thereof. However, these approaches are not always effective and can have serious side effects. Alternative strategies are being developed, based on stimulating the body’s immune system to eliminate the tumor and prevent a recurrence. These include a range of biological therapies. Some of them activate dendritic cells, which direct the activation of the T lymphocytes that kill the tumor cells. Cell based therapies, involving infusion of cell culture expanded T lymphocytes or dendritic cells are also in development.

Some of these approaches are effective against a small range of tumors. For example, a Toll-like receptor (TLR) agonist, called imiquimod, which activates dendritic cells, is in clinical use as a topical application for basal cell carcinoma. In addition, a number of TLR agonists have been evaluated in clinical trials as an adjuvant for cancer vaccines. However there have also been disappointing results from clinical trials involving TLR agonists.

A problem with TLR agonists and other therapeutic and vaccine approaches against cancer that have not been fully appreciated is that they can generate suppressive as well as inflammatory responses in innate immune cells and can generate regulatory as well as protective T cells. This is part of a normal mechanism for limiting collateral damage during infection or inflammation, but can constrain their ability to induce protective anti-tumor immunity in the immune suppressed environment of the tumor.

Mills and co-workers have developed an approach to manipulate the TLR-activated innate immune responses to selectively block the suppressive arm. The scientists achieved this by manipulating intracellular signalling pathways in the dendritic cells, thereby blocking the induction of Treg cells and immunosuppressive responses and promoting the protective responses that eliminate the tumors. The new approach has proven very successful in prevent cancer in a tumor models in mice and may hold the key to enhancing the efficacy of tumor immunotherapeutics and vaccines against cancer in humans. The new technology has been licensed to a local start-up company, Opsona Therapeutics, who are planning to move it into clinical development in partnership with major pharmaceutical companies.


Story Source:

The above story is based on materials provided by Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. Note: Materials may be edited for content and length.


Cite This Page:

Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. "Regulating The Regulators: New Therapeutic Approach Against Cancer." ScienceDaily. ScienceDaily, 21 September 2009. <www.sciencedaily.com/releases/2009/09/090916092542.htm>.
Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. (2009, September 21). Regulating The Regulators: New Therapeutic Approach Against Cancer. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2009/09/090916092542.htm
Deutsche Gesellschaft fuer Immunologie e.V./German Society for Immunology. "Regulating The Regulators: New Therapeutic Approach Against Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/09/090916092542.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins